Business
AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test
AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company has signed an exclusive limited licensing, manufacturing and distribution agreement with Empowered Diagnostics LLC (“Empowered Diagnostics”) for high volume production of AXIM’s rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Empowered Diagnostics will manufacture the lateral flow assay tests under the name Tru-19 Neutralizing Antibody Test (the “Test”). Empowered Diagnostics, based in Pompano Beach, Florida, is a large volume manufacturer and distributor of cost-effective rapid point-of-care diagnostic solutions.  In 2019, Empowered Diagnostics purchased one of the nation’s largest capacity manufacturers of diagnostics tests and is developing propriety innovations to provide the most efficient test production facility in the World.   “Axim’s second-generation tests measures the antibodies that block the disease from getting into our cells, which is a much better way to detect immunity than the current rapid tests in the market,” said Rick Hennessey, CEO of Empowered Diagnostics. “During this time, people need assurance of immunity so they can safely get back to school, work and their daily lives.” Due to the urgency of the COVID-19 pandemic, Empowered Diagnostics is adding a new automated inline large-scale production capacity, which when installed will be able to manufacture millions of tests per week. Empowered has partnered with a large national sales organization that currently owns labs and sells in-house services and tests to many other independent labs across the country. The sales organization will focus on large employer groups, clinical research companies, health care organizations, professional sports and entertainment venues and academic organizations. “Our goal in creating our rapid lateral flow assay was to provide as many people as possible with an easy-to-use, accurate and quick tool for measuring their COVID-19 neut...